<SEC-DOCUMENT>0001104659-25-116274.txt : 20251126
<SEC-HEADER>0001104659-25-116274.hdr.sgml : 20251126
<ACCEPTANCE-DATETIME>20251126101044
ACCESSION NUMBER:		0001104659-25-116274
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20251126
FILED AS OF DATE:		20251126
DATE AS OF CHANGE:		20251126

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CureVac N.V.
		CENTRAL INDEX KEY:			0001809122
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39446
		FILM NUMBER:		251525460

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		FRIEDRICH-MIESCHER-STRASSE 15
		CITY:			TUBINGEN
		NON US STATE TERRITORY:  	BADEN-WURTTEMBERG
		PROVINCE COUNTRY:   	2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 9883 0

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		FRIEDRICH-MIESCHER-STRASSE 15
		CITY:			TUBINGEN
		NON US STATE TERRITORY:  	BADEN-WURTTEMBERG
		PROVINCE COUNTRY:   	2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CureVac B.V.
		DATE OF NAME CHANGE:	20200410
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2532279d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM&nbsp;6-K</B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPORT OF FOREIGN PRIVATE
ISSUER<BR>
PURSUANT TO RULE&nbsp;13a-16 OR 15d-16<BR>
UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For the month of November&nbsp;2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Commission File Number:
001-39446</B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CureVac N.V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(<I>Exact Name of Registrant
as Specified in Its Charter</I>)</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Friedrich-Miescher-Strasse
15, 72076</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>T&uuml;bingen, Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>+49 7071 9883 0</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(<I>Address of principal
executive office</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form&nbsp;20-F&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&#120;</FONT>
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Form&nbsp;40-F&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yes&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT>
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yes&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT>
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 25, 2025, CureVac N.V. (the &ldquo;Company&rdquo;) issued
a press release announcing the voting results of the Company&rsquo;s extraordinary general meeting of shareholders, including a table
containing tabulations of the votes cast.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information included in this Form&nbsp;6-K&nbsp;(including Exhibit
99.1) shall be deemed to be filed and incorporated by reference in BioNTech SE&rsquo;s registration statement on Form&nbsp;F-4&nbsp;(File&nbsp;No.
333-289468)&nbsp;and to be part thereof from the date on which this Form&nbsp;6-K is filed, to the extent not superseded by documents
or reports subsequently filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CureVac N.V.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: </FONT><FONT STYLE="font-size: 10pt">November
    26, 2025</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    </FONT><FONT STYLE="font-size: 10pt">Alexander Zehnder</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief
    Executive Officer</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT&nbsp;INDEX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 12%">EXHIBIT&nbsp;NO.</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 87%">DESCRIPTION</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><A HREF="tm2532279d1_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tm2532279d1_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CureVac N.V. Press Release dated November 25, 2025</FONT></A></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2532279d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><IMG SRC="tm2532279d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CureVac Announces Voting Results of Extraordinary
General Meeting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>T&Uuml;BINGEN, Germany / BOSTON, USA</B> &ndash; November&nbsp;25,
2025 &ndash; CureVac N.V. (Nasdaq: CVAC)(CureVac or the Company), a pioneering multinational biotech company developing a new class of
transformative medicines based on messenger RNA (mRNA), today announced the voting results of its Extraordinary General Meeting (EGM).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CureVac&rsquo;s shareholders approved all proposals relating to BioNTech
SE&rsquo;s public exchange offer for all outstanding shares in CureVac (Offer) at the EGM with an approval rate of over 99.16% of the
votes cast.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Offer is set to expire at 9:00 am Eastern Time on December&nbsp;3,
2025, with CureVac&rsquo;s shareholders advised to tender their shares by 6:00 pm Eastern Time on December&nbsp;2, 2025, due to operational
deadlines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Voting results &ndash; Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A table containing tabulations of the votes cast is set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #A6A6A6">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Agenda Item 3</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consummation of post-offer reorganization</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agenda Item 3.a.</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditional resolution to enter into a legal merger (<I>juridische fusie</I>) of the Company (as disappearing company) with and into CureVac Merger B.V. (as acquiring company surviving such merger) (New Topco), with New Topco issuing class A shares in its capital to the Company&rsquo;s shareholders (other than BioNTech SE (Buyer)) and class B shares in its capital to Buyer, in accordance with Sections 2:309 et seq. of the Dutch Civil Code (the Legal Downstream Merger) &ndash; accepted</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">158,803,292</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of shares for which valid votes were cast (= 70.52% of the registered share capital)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">158,646,068</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; width: 25%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes votes</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; width: 54%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.95% of the valid votes cast</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">84,255</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No votes</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.05% of the valid votes cast</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agenda Item 3.b.</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditional resolution to approve, to the extent required under applicable law and the Company&rsquo;s articles of association and bylaws (<I>reglementen</I>), (i)&nbsp;the Legal Downstream Merger, (ii)&nbsp;the subsequent sale and transfer of all outstanding shares in the capital of CureVac SE by New Topco to Buyer and (iii)&nbsp;the subsequent cancellation of all outstanding class A shares in the capital of New Topco &ndash; accepted</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">158,803,292</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of shares for which valid votes were cast (= 70.52% of the registered share capital)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">158,639,956</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes votes</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.94% of the valid votes cast</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">89,164</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No votes</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.06% of the valid votes cast</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><IMG SRC="tm2532279d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #A6A6A6">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Agenda Item 4</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conditional release from liability</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agenda Item 4.a.</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditional release of managing directors from liability for the exercise of their duties &ndash; accepted </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">158,803,292</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of shares for which valid votes were cast (= 70.52% of the registered share capital)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; width: 21%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">157,535,455</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes votes</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; width: 54%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.27% of the valid votes cast</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,165,859</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No votes</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.73% of the valid votes cast</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agenda Item 4.b.</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditional release of supervisory directors from liability for the exercise of their duties &ndash; accepted</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">158,803,292</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of shares for which valid votes were cast (= 70.52% of the registered share capital)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">157,485,433</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes votes</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.23% of the valid votes cast</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,219,313</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No votes</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.77% of the valid votes cast</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #A6A6A6">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Agenda Item 5</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conditional appointment of Ram&oacute;n Zapata Gomez as managing director of the Company &ndash; accepted</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">158,803,292</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of shares for which valid votes were cast (= 70.52% of the registered share capital)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">157,414,993</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes votes</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.89% of the valid votes cast</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">171,497</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No votes</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.11% of the valid votes cast</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #A6A6A6">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Agenda Item 6</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conditional appointment of supervisory directors</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agenda Item 6.a.</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditional appointment of Sierk Poetting as supervisory director of the Company &ndash; accepted</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">158,803,292</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of shares for which valid votes were cast (= 70.52% of the registered share capital)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">156,296,489</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes votes</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.18% of the valid votes cast</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,289,511</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No votes</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.82% of the valid votes cast</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><IMG SRC="tm2532279d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agenda Item 6.b.</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditional appointment of James Ryan as supervisory director of the Company &ndash; accepted</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">158,803,292</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of shares for which valid votes were cast (= 70.52% of the registered share capital)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; width: 21%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">156,260,667</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes votes</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; width: 54%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.16% of the valid votes cast</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,327,264</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No votes</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.84% of the valid votes cast</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agenda Item 6.c.</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditional appointment of Annemarie Hanekamp as supervisory director of the Company &ndash; accepted </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">158,803,292</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of shares for which valid votes were cast (= 70.52% of the registered share capital)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">156,257,812</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes votes</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.16% of the valid votes cast</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,327,765</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No votes</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.84% of the valid votes cast</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About CureVac</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company
founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of
developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined
key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork
for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics
and computational tools, to design and develop off-the-shelf and personalized precision immunotherapy candidates to treat cancer. It also
develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins. Headquartered
in T&uuml;bingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information can
be found at <U>www.curevac.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CureVac Media and Investor Relations Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CureVac, T&uuml;bingen, Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Corporate Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">communications@curevac.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2532279d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements of CureVac</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains statements that constitute &ldquo;forward
looking statements&rdquo; as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements
that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned
subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac Belgium
SA and CureVac Netherlands B.V. (the &ldquo;company&rdquo;) regarding future events or future results, in contrast with statements that
reflect historical facts. Examples include the settlement of all pending patent disputes in the United States between the company, Pfizer,
and BioNTech relating to mRNA-based COVID-19 vaccines, the Company's expectations regarding the outcome of pending litigation in other
global jurisdictions, the expected completion of the public exchange offer between BioNTech and the Company, the discussion of the potential
efficacy of the company&rsquo;s vaccine and treatment candidates and the company&rsquo;s strategies, financing plans, cash runway expectations,
the timing and impact of restructuring, growth opportunities and market growth. In some cases, you can identify such forward-looking statements
by terminology such as &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;plan,&rdquo;
 &ldquo;seek,&rdquo; &ldquo;project,&rdquo; &ldquo;expect,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo;
 &ldquo;potential,&rdquo; &ldquo;intend,&rdquo; or &ldquo;should,&rdquo; the negative of these terms or similar expressions. Forward-looking
statements are based on management&rsquo;s current beliefs and assumptions and on information currently available to the company. However,
these forward-looking statements are not a guarantee of the company&rsquo;s performance, and you should not place undue reliance on such
statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including risks related
to the proposed acquisition by BioNTech, negative worldwide economic conditions and ongoing instability and volatility in the worldwide
financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing,
expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products,
ability to manufacture any products, ability to implement our pipeline strategy, possible changes in current and proposed legislation,
regulations and governmental policies, pressures from increasing competition and consolidation in the company&rsquo;s industry, the effects
of the COVID-19 pandemic on the company&rsquo;s business and results of operations, ability to manage growth, ability to implement, maintain
and improve effective internal controls, reliance on key personnel, reliance on intellectual property protection, ability to provide for
patient safety, fluctuations of operating results due to the effect of exchange rates, delays in litigation proceedings, the impact of
adverse settlements or other judicial outcomes and other important factors discussed under the caption &ldquo;Risk Factors&rdquo; in the
company&rsquo;s annual report on Form&nbsp;20-F filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on April&nbsp;11,
2025, as such factors may be updated form time to time in its other filings with the SEC. Such risks and uncertainties may cause the statements
to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company&rsquo;s
control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included
in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to
update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments,
except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For further information, please reference the company&rsquo;s reports
and documents filed with the SEC. You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2532279d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2532279d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  [ *(# 2(  A$! Q$!_\0
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2\]1N8-@]1D ^H!XHJ[10!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
